ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
67,607.10
0.19%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. aTyr Pharma Inc (LIFE)

  7. aTyr Pharma Inc (LIFE) 뉴스

LIFE

aTyr Pharma (LIFE)

aTyr Pharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LIFE
일자시간출처헤드라인심볼기업
2024/05/3005:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
2024/05/2505:00GlobeNewswire Inc.aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LIFEaTyr Pharma Inc
2024/05/2408:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/05/2408:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/05/2408:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/05/2408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/05/1520:00GlobeNewswire Inc.aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International ConferenceNASDAQ:LIFEaTyr Pharma Inc
2024/05/1421:00GlobeNewswire Inc.aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:LIFEaTyr Pharma Inc
2024/05/0621:00GlobeNewswire Inc.aTyr Pharma to Present at Upcoming Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
2024/05/0305:00GlobeNewswire Inc.aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
2024/04/0121:00GlobeNewswire Inc.aTyr Pharma to Participate in April Investor ConferencesNASDAQ:LIFEaTyr Pharma Inc
2024/03/1505:00GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
2024/02/2822:00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsNASDAQ:LIFEaTyr Pharma Inc
2024/02/2122:00GlobeNewswire Inc.aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial ParticipantsNASDAQ:LIFEaTyr Pharma Inc
2024/02/0710:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/02/0710:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/2922:00GlobeNewswire Inc.aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell DiversityNASDAQ:LIFEaTyr Pharma Inc
2024/01/1822:00GlobeNewswire Inc.aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as AdvisorNASDAQ:LIFEaTyr Pharma Inc
2024/01/1009:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/1009:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2024/01/0302:21Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIFEaTyr Pharma Inc
2023/12/1308:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2023/11/2114:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIFEaTyr Pharma Inc
2023/11/1406:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIFEaTyr Pharma Inc
2023/11/1322:00GlobeNewswire Inc.aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023NASDAQ:LIFEaTyr Pharma Inc
2023/11/1007:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIFEaTyr Pharma Inc
2023/11/1006:00GlobeNewswire Inc.aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdateNASDAQ:LIFEaTyr Pharma Inc
 검색 관련기사 보기:NASDAQ:LIFE

최근 히스토리

TSXV
NXH
Next Hydrogen Solutions
USOTC
HTCCY
HTC (PK)
BIT
UC7YRX
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유